Navigation Links
Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011
Date:7/27/2011

with the year-ago period in North America.

"Continued strong demand for our TrueBeam platform and service contracts led to the order and revenue growth during the quarter," Guertin said. "Our TrueBeam platform for radiotherapy and radiosurgery represented more than 40 percent of all machines ordered during the quarter.  This platform enabled us to gain market share in North America while driving growth in international markets with major wins in Scotland, Norway, and Saudi Arabia."

X-Ray ProductsThird quarter revenues from x-ray tubes and flat panel image detectors for filmless imaging were $121 million, up 18 percent from the year-ago quarter.  Compared to the same period in fiscal year 2010, X-Ray Products' third quarter net orders rose 17 percent to $121 million."Demand for our full range of products remained strong in the third quarter," said Guertin.  "X-ray tubes for CT scanners, mammography, and service replacement tubes grew at a double-digit pace."  The overall growth of X-Ray Products segment continued to be led by its radiographic imaging panels that were introduced last year.

OtherThe company's Other category, which is comprised of the Security and Inspection Products (SIP) business, the Varian Particle Therapy business, and the Ginzton Technology Center, recorded third quarter revenues of $16 million, down 18 percent from the year-ago period.  Net orders in the company's Other category were $17 million, down 12 percent from the year-ago quarter.

Outlook "We continue to estimate that revenues for fiscal year 2011 could grow 10 to 11 percent over the fiscal 2010 total," said Guertin. "We now believe that net earnings per diluted share from continuing operations for the year could grow by about 16 percent to be in the range of $3.42 to $3.45."  

Investor Conference CallVarian Medical Systems is scheduled to conduct its third quarter fiscal year 2011 conference call at 2 p
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Research and ... of the  "2015 Strategies in the Global ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... of the orthopedics market, including forecasts for ... categories. , ,In addition, the report presents ...
(Date:5/27/2015)... Research and Markets ( ... the  "North America Mammography Market - Growth, ...  report to their offering.      ... detailed type of imaging that customs a ... mammography exam, called a mammogram, is used ...
(Date:5/27/2015)... 27, 2015 OpportunityAnalyzer: Sepsis - Opportunity Analysis ... suffer from a series of diverse complications arising from ... blood or tissues, which cause a rapidly progressing hyperactive ... rates near 50% depending on disease severity. The syndrome ... of the global marketplace, which for the purposes of ...
Breaking Medicine Technology:Global Orthopedics Market Strategies 2015 2North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4
... 2012   CANTEL MEDICAL CORP. (NYSE:CMN) announced today ... presenting at the Needham & Company, LLC  14th Annual ... AM ET on Wednesday, January 11, 2012 at The ... session immediately following the presentation. In addition, Mr. Krakauer ...
... 4, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), ... focused on cardiac and vascular surgery, announced today that ... position of Vice President, Research and Development; and David ... President, Market Development Surgical Adhesives and Starch Medical Relations.  ...
Cached Medicine Technology:CryoLife Enhances Management Team with Promotions 2CryoLife Enhances Management Team with Promotions 3CryoLife Enhances Management Team with Promotions 4CryoLife Enhances Management Team with Promotions 5
(Date:5/27/2015)... California (PRWEB) May 27, 2015 Western ... marked by a few historic firsts -- and one ... the Pasadena Civic Center marked the first time the ... the first time a Graduate College of Biomedical Sciences ... of the Pacific (COMP). , The university’s fifth and ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 “We are ... Schuller, MD, executive vice president and vice president of ... grant makes possible allows us to provide comprehensive care ... our community.” , SSCHC provides clinical care and behavioral ... 35,000 people in 2014, many of whom took advantage ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 While hair ... hair loss, a new pilot study conducted by a ... Surgery (ISHRS) has found hair follicle grafting can help ... research was partially funded by ISHRS, which offers research ... to hair restoration. , In the past decade, ...
(Date:5/27/2015)... 2015 NOVAtime Technology, Inc. ( ... solutions for enterprise organizations, announced today that SanMar ... automate its time, attendance and point tracking processes ... the United States. , Family-owned since 1971, ... 21 retail, private label, and mill brands. SanMar ...
(Date:5/27/2015)... ABILENE, Texas (PRWEB) May 27, 2015 ... addition of three FDA-approved dermal filler treatments in Abilene, ... designed to reduce the appearance of glabellar lines, better ... lines. Belotero Balance® is designed to treat smoker’s ... mouth to the chin, while Radiesse® improves the appearance ...
Breaking Medicine News(10 mins):Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 2Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 3Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 4Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 5Health News:Sixteenth Street Community Health Centers To Expand Primary Care and Behavioral Health Services Through $1 Million Grant From Aurora's Better Together Fund 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2
... The California Alliance for Inclusive Communities (CAIC) has recently ... 374. They join the majority of state and national ... is an advocacy group that works on behalf of ... ,Just as a new national AP/Ipsis poll ...
... new report released today by the Pharmaceutical Research and ... testing 277 medicines for two of the three leading ... and stroke. The medicines are currently in clinical trials ... (FDA). ,'Heart disease and stroke are still ...
... advent of a possible new blockbuster drug and greater ... drug addictions, global sales of smoking cessation and ... little over $1.1 billion in 2005 to more than ... Addiction Treatments: A World Market Analysis, a new study ...
... effects on cardiometabolic risk factors beyond those expected from ... may not be due to the drug itself, reports ... Therapeutics Bulletin (DTB). ,Advertisements for rimonabant ... that an estimated 50% of the effects on ...
... year the last day of May is celebrated as the ... World Health Organization to wag a warning finger at the ... This year the focus is on 100% smoke free ... to tobacco. There is also an effort to highlight the progress ...
... smokers today by declaring the site of the Beijing Olympics a ... Olympic venues and restaurants," The Telegraph quoted Zhang Jianshu, a city ... issue can raise has already been seen at the stadiums for ... by security guards to stop construction workers taking a cigarette break ...
Cached Medicine News:Health News:More Than 270 Medicines in Testing for Heart Disease and Stroke 2Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2Health News:Stop Smoking, Start Living: World No Tobacco Day 2Health News:Stop Smoking, Start Living: World No Tobacco Day 3Health News:Stop Smoking, Start Living: World No Tobacco Day 4Health News:China Bans Smoking at Olympics 2
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
For the qualitative detection of group A Streptococcal antigen from throat swabs...
Medicine Products: